| pubmed-article:10493837 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C0008109 | lld:lifeskim |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C0015295 | lld:lifeskim |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C0449416 | lld:lifeskim |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C1514468 | lld:lifeskim |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C1880371 | lld:lifeskim |
| pubmed-article:10493837 | lifeskim:mentions | umls-concept:C0908880 | lld:lifeskim |
| pubmed-article:10493837 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10493837 | pubmed:dateCreated | 1999-11-22 | lld:pubmed |
| pubmed-article:10493837 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:abstractText | In the Ewing family of tumors (EFT), the EWS gene is rearranged with members of the ets oncogene family. Variability in genomic breakpoint locations is the source of significant heterogeneity in fusion product structure. As a consequence of variably included exon sequences from the two partner genes, a variable amount of additional peptide sequence is inserted in between the minimal transforming domains. Some of this molecular diversity has recently been correlated with disparate clinical outcome. Here we report on cryptic exons found in the chimeric RNA of three EFT with different EWS-FLI1 fusions. In two tumors, the emergence of a cryptic exon from FLI1 intron 5 in the chimeric RNA was apparently unrelated to the genomic rearrangement that occurred in FLI1 introns 4 and 5, respectively. In one case, a novel exon was generated through the creation of an artificial splice acceptor site in FLI1 intron 6 by the genomic rearrangement that occurred in EWS intron 8. These results further extend the spectrum of molecular diversity in EFT. | lld:pubmed |
| pubmed-article:10493837 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10493837 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10493837 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10493837 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10493837 | pubmed:issn | 0888-7543 | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:ThomasGG | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:LenoirGG | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:PhilipII | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:MelotTT | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:ZoubekAA | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:Turc-CarelCC | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:FinkF MFM | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:KovarHH | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:JugovicDD | lld:pubmed |
| pubmed-article:10493837 | pubmed:author | pubmed-author:Zucman-RossiJ... | lld:pubmed |
| pubmed-article:10493837 | pubmed:copyrightInfo | Copyright 1999 Academic Press. | lld:pubmed |
| pubmed-article:10493837 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10493837 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10493837 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:10493837 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10493837 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10493837 | pubmed:pagination | 371-4 | lld:pubmed |
| pubmed-article:10493837 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:meshHeading | pubmed-meshheading:10493837... | lld:pubmed |
| pubmed-article:10493837 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10493837 | pubmed:articleTitle | Cryptic exons as a source of increased diversity of Ewing tumor-associated EWS-FLI1 chimeric products. | lld:pubmed |
| pubmed-article:10493837 | pubmed:affiliation | Children's Cancer Research Institute, St. Anna Kinderspital, Vienna, Austria. kovar@ccri.univie.ac.at | lld:pubmed |
| pubmed-article:10493837 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10493837 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:10493837 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
